Subscribe To

Price Alert Latest News Economic Calendar News

EDIT / Why Editas Medicine Stock Is Soaring Today

Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progress in developing a gene-editing therapy targeting sickle cell disease. Read More

Demo Live Account See Partner Details

Content Topics

Editas

Medicine

Stock

Soaring

Today

EDIT

Posted: Sep 29 2023, 11:21

Author Name: The Motley Fool

EDIT News

By Zacks Investment Research
November 3, 2023

Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss

By GlobeNewsWire
November 2, 2023

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to

By Zacks Investment Research
October 17, 2023

Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD

The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickl

By The Motley Fool
October 7, 2023

Is Editas Stock a Buy Now?

Editas uses an untraditional gene-editing technique. The company is in the clinical stage with no approved therapies yet.

By The Motley Fool
October 5, 2023

Avoid Big Losses With Biotech Stocks by Paying Attention to These 2 Things

Biotech stocks are highly risky even when they're notching successes. Issuing stock and taking out debt are not equivalent risks for shareholders.

By Seeking Alpha
October 3, 2023

Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena

Editas Medicine's reduced R&D costs and strong cash position provide operational comfort but necessitate future capital, especially amid looming compe

By The Motley Fool
September 29, 2023

Why Editas Medicine Stock Is Soaring Today

Stifel upgraded Editas Medicine stock from hold to buy and raised the price target from $9 to $17. The upgrade reflects optimism about Editas' progres

By Seeking Alpha
September 7, 2023

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo Securities Healthcare Conference Call Transcript

Editas Medicine, Inc. (NASDAQ:EDIT ) Wells Fargo Securities Healthcare Conference Call September 7, 2023 3:00 PM ET Company Participants Gilmore O'Nei

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.